{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-021347","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2022-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.034032+00:00","generated_at":"2026-06-24T03:25:34.501068+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcutis Biotherapeutics closes underwritten public offering of 8.625M shares at $20, net proceeds ~$161.7M","bullets":["Sold 7.5M shares plus full exercise of over-allotment of 1.125M shares at $20 per share.","Net proceeds approximately $161.7M after underwriting discounts and expenses.","Proceeds to fund development, approval, commercial launch for ZORYVE and general corporate purposes.","Underwriters include Morgan Stanley, Cowen, Guggenheim Securities."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-021347","json":"https://secwatch.observer/filing/0001628280-22-021347.json","markdown":"https://secwatch.observer/filing/0001628280-22-021347.md","text":"https://secwatch.observer/filing/0001628280-22-021347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000162828022021347/0001628280-22-021347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000162828022021347/arqt-20220802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:25:34.501068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}